Expected timeline: Month 1-2: Inflammation management, symptomatic improvement Month 3-6: Potential slowing of degenerative markers, quality of life improvement Month 6-12: Assessment of structural changes, protocol optimization Ongoing: Maintenance protocols as needed, cycling strategies Complementary approaches: Anti-inflammatory nutrition
Yes, ARA-290 has been investigated in multiple Phase 2 clinical trials, including studies in sarcoidosis-associated neuropathy and metabolic parameters in type 2 diabetes
Citalopram, a selective serotonin reuptake inhibitor that enhances serotonergic neurotransmission by blocking serotonin reuptake at the presynapse, restored motor coordination, aggregation, and neuronal survival in mice, and aripiprazole, an antipsychotic whose efficacy mainly reflects a combined action on dopaminergic and serotonergic signaling, reduced abundance, aggregation, and toxicity of mutant ATXN3 in vivo
The arginine salt form is cited in the patents as superior for absorption, though head-to-head clinical data confirming that advantage dont yet exist
60 Suppl 7, pp
